Shanghai Miracogen Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2013)

Organization Overview

First Clinical Trial
2018
NCT04868344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shanghai Miracogen Inc.

Active Ingredients

Drugs in Phase 3 Trials (8)

cetuximab (erbitux) (1 trial)

docetaxel (taxotere) (1 trial)

gemcitabine (gemzar) (1 trial)

methotrexate (1 trial)

mrg002 (11 trials)

mrg003 (8 trials)

paclitaxel (taxol) (1 trial)

pemetrexed (alimta) (1 trial)

Drugs in Phase 2 Trials (2)

hx008 (2 trials)

mrg004a (1 trial)

Drugs in Phase 1 Trials (1)

mrg001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 11